Regel Therapeutics
Pre-clinicalUsing its proprietary Targeted EpiEditing platform, Regel develops novel therapeutic approaches for the treatment of severe genetic diseases.
Founded
2021
Focus
RNA & Gene TherapyViral Technology
About
Using its proprietary Targeted EpiEditing platform, Regel develops novel therapeutic approaches for the treatment of severe genetic diseases.
Funding History
1Total raised: $15M
Seed$15MThird Rock VenturesJun 15, 2022
Company Info
TypePrivate
Founded2021
LocationCambridge, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile